Apolipoprotein polymorphisms fail to define risk of coronary artery disease. Results of a prospective, angiographically controlled study.

Marshall, Hiram W.; Morrison, Linda; Wu, Lily; Anderson, Jeffrey L.; Corneli, Patrice Showers; Stauffer, Dora; Allen, April N.; Karagounis, Labros A.; Ward, Ryk

doi:10.1161/01.cir.89.2.567

Cited by 62 publications

(23 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Marshall et al found no evidence that the apoB Ins/Del polymorphism had a significant influence on the risk of angiographically defined CAD. 39 In contrast, Hong et al observed that the Ins allele frequency was significantly higher in patients than in healthy controls in a Korean case control study with 216 controls and 235 CAD patients. 26 In order to generate robust data on apoB gene (EcoRI, XbaI, and SpIns/Del) polymorphisms and CAD risk, we carried out an update meta-analysis involving 54 studies and focusing on worldwide studies to provide the most comprehensive analysis on the relationship between apoB gene polymorphisms and CAD risk.…”

Section: Discussionmentioning

confidence: 89%

Association between apolipoprotein B gene polymorphisms and the risk of coronary heart disease (CHD): an update meta-analysis

Zhang

Zheng

Yang

et al. 2015

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

Objective: Polymorphisms in the apolipoprotein B (apoB) gene have been reported to be associated with coronary heart disease (CHD). However, the results on this topic are conflicting. The present study aims to derive a more precise estimation of the relationship between CHD and apoB genetic polymorphisms by meta-analysis. Methods:We identified a total of 54 studies involving 7236, 10,912, and 14,102 individuals, respectively, for EcoRI, XbaI, and SpIns/Del polymorphisms by searching in PubMed, Web of Science, Google Scholar, the Cochrane Library, Wanfang Data, SinoMed, and CNKI. We utilized RevMan 5.0 software to perform the meta-analyses. Results: A significant statistical association between apoB EcoRI polymorphism and CHD was observed under an allelic (p = 0.001, odds ratio (OR) = 1.33, 95% confidence interval (CI) = 1.12-1.57), dominant (p = 0.005, OR = 1.22, 95% CI = 1.06-1.40), and recessive (p = 0.04, OR = 1.33, 95% CI = 1.01-1.74) model. We also found similar association of apoB SpIns/Del polymorphism with CHD. However, we did not find association between apoB XbaI polymorphism and CHD. Conclusion:The current meta-analysis found an association of EcoRI polymorphism and SpIns/Del polymorphism with an increased risk of CHD. No significant association between apoB XbaI polymorphism and CHD we observed in the present study.

show abstract

Section: Discussionmentioning

confidence: 89%

Association between apolipoprotein B gene polymorphisms and the risk of coronary heart disease (CHD): an update meta-analysis

Zhang

Zheng

Yang

et al. 2015

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

show abstract

“…Thus, APOB is critical for the synthesis, transport, and catabolism of TG-rich and cholesterol-rich lipoproteins in the intestine and liver ( 11,12 ). Polymorphisms in the APOB gene have been associated with the variability of serum cholesterol levels and coronary atherosclerosis in some populations ( 13 ) but not all ( 14 ). No studies have examined the role of APOB genetic variants in relation to the lipid-lowering effects of fenofi brate.…”

Section: Discussionmentioning

confidence: 99%

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study

Wojczynski

Gao

Borecki³

et al. 2010

Journal of Lipid Research

View full text Add to dashboard Cite

“…The e4 allele has been implicated in some studies as a risk factor for CAD (11,42,(45)(46)(47), although others have failed to find such an association, including a prospective angiographic study (37,(48)(49)(50). In the Scandinavian Simvastatin Survival Study, Gerdes et al (12) concluded that patients carrying the e4 allele have an 80% increased risk of coronary death compared with patients not carrying the allele.…”

Section: Discussionmentioning

confidence: 99%

Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol

Anuurad

Rubin

et al. 2006

Journal of Lipid Research

View full text Add to dashboard Cite

We studied the relationship of apolipoprotein E (apoE) isoforms and coronary artery disease (CAD) in 224 African Americans and 326 Caucasians undergoing diagnostic coronary angiography. The presence of CAD was defined as .50% stenosis in at least one artery. ApoE allele frequencies were 0.12, 0.62, and 0.26 for e2, e3, and e4, respectively, in African Americans and 0.08, 0.78, and 0.14 for e2, e3, and e4, respectively, in Caucasians. Among African Americans, CAD was present in 9 of 34 e2 carriers (26%), significantly smaller (P , 0.05) in proportion compared with 39 of 82 e3 carriers and 43 of 92 e4 carriers (48% and 47%, respectively), suggesting a protective effect of the e2 allele. No such difference was seen in Caucasians. In African Americans but not Caucasians, LDL cholesterol was lower in e2 carriers than in e3 and e4 carriers (106 vs. 127 and 134 mg/dl, respectively; P , 0.005). After adjusting for lipid levels, the association between apoE2 and CAD was no longer significant. Thus, the protective effect of apoE2 seen in African Americans could be explained by a favorable lipid profile in e2 carriers, whereas in Caucasians, the absence of such a protective effect could be attributable to the lack of effect of apoE2 on the lipid

show abstract

Apolipoprotein polymorphisms fail to define risk of coronary artery disease. Results of a prospective, angiographically controlled study.

Cited by 62 publications

References 39 publications

Association between apolipoprotein B gene polymorphisms and the risk of coronary heart disease (CHD): an update meta-analysis

Association between apolipoprotein B gene polymorphisms and the risk of coronary heart disease (CHD): an update meta-analysis

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study

Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol

Contact Info

Product

Resources

About